EGFR inhibitors are considered as a hopeful strategy for cancer therapy in diverse EGFR+ cancers clinically: Gefitinib (Ge, small molecules EGFR tyrosine kinases inhibitor), which inhibits cancer growth mainly through targeting the adenosine triphosphate binding sites in the cytoplasmic domain of EGFR, is widely applied in non-small-cell lung cancer (NSCLC); Cetuximab (monoclonal antibody) was approved in colorectal cancer, etc. Unfortunately, their efficacy for breast cancer is limited due to drug resistance [9]. Here, EGFR is linked to non-small cell lung carcinoma.